SAN FRANCISCO, California, United States, September 2025 — PJ Iranitalab has been elevated to the role of Chief Operating Officer at Axon Therapies Inc., marking a new chapter in his extensive journey with the company.
At Axon Therapies Inc., he has served in various strategic and technical leadership roles, including overseeing engineering and operations. He has played a pivotal role in advancing product development, validation processes, quality systems, and regulatory compliance. His tenure has been defined by consistent contributions across medical device R&D, systems engineering, and operational scale-up.
Before this, he worked at Boston Scientific, following its acquisition of Apama Medical, where he led research and development initiatives, driving innovation and compliance in high-impact projects.
Earlier, at Apama Medical, he contributed significantly to operations and process development, directing multiple R&D programs and ensuring alignment with regulatory and strategic objectives.
Prior to that, he was associated with Cardica, Inc., where he oversaw R&D functions and led end-to-end medical device development initiatives. He also contributed to advanced surgical tools and catheter systems with strong emphasis on FDA compliance and V&V standards.
His previous experiences span several organizations including Stryker, St. Jude Medical, Boston Scientific, and PJ’s Software Consulting, where he took on key roles in product development, software and systems engineering, team leadership, and research across a range of medical devices and life-saving technologies.
About Axon Therapies Inc.
Axon Therapies Inc. is revolutionizing the treatment of heart failure by addressing one of its root causes—chronic overactivation of the sympathetic nervous system (SNS). Through its innovative frontline therapy, Axon selectively ablates the neural pathway responsible for carrying signals from the SNS, aiming to restore volume balance, halt disease progression, and enhance patient outcomes. As a pioneering force in the cardiovascular space, Axon is committed to improving the lives of millions affected by heart failure.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
